<DOC>
	<DOCNO>NCT02860858</DOCNO>
	<brief_summary>Objective : To evaluate efficacy intravitreal aflibercept injection visual acuity patient symptomatic macular PCV .</brief_summary>
	<brief_title>Intravitreal Aflibercept Treatment Polypoidal Choroidal Vasculopathy ( PCV )</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Male Female &gt; /= 18 year Confirmed diagnosis symptomatic macular PCV study eye define : Active macular polypoidal lesion show ICGA Presence serosanguinous maculopathy BCVA letter score 7824 use ETDRS visual acuity chart measure 4 meter Previous treatment systemic antiVEGF drug within 6 month prior Baseline ( e.g. , sorafenib [ Nexavar® ] , sunitinib [ Sutent® ] , bevacizumab [ Avastin® ] ) Study eye : Active ocular inflammation infection ( ocular periocular ) Uncontrolled intraocular hypertension glaucoma ( IOP &gt; 30 mmPIg ) despite treatment antiglaucoma medication Predominantlyscarred PCV lesion Ocular disorder study eye ( e.g . cataract , retinal vascular occlusion , diabetic retinopathy ) , opinion investigator may confound interpretation study result compromise VA require medical surgical intervention study period Prior treatment verteporfin PDT , externalbeam radiation , subfoveal extrafoveal focal laser photocoagulation , submacular surgery , transpupillary thermotherapy Prior treatment antiVEGF compound investigational treatment Treatment intravitreal subtenon corticosteroid injection device implantation within 90 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>